RoosterBio, a supplier of adult human mesenchymal stem/stromal cells (hMSCs), engineered media, and bioprocess development services, entered into a collaboration with Thermo Fisher Scientific which aims to accelerate the availability of new cell and exosome therapies that have the potential to greatly improve the treatment of degenerative disease.
The combination of RoosterBio’s portfolio of hMSC-based products and processes with Thermo Fisher’s advanced therapy GMP contract manufacturing capabilities is designed to offer a new solution for the development and manufacture of hMSC and exosome therapeutics, noted officials at both companies.
Specifically, according to Tim Kelly, CEO of RoosterBio, biopharmaceutical companies will be able to utilize RoosterBio’s and Thermo Fisher’s complementary skills to accelerate their timelines for production of clinical trial materials. Manufacturing services provided by Thermo Fisher will include upstream expansion of hMSCs, downstream purification of MSCs and MSC-derived exosomes, and drug product manufacturing.
“Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities,” said Kelly. “Through this collaboration, we will deliver that comprehensive solution to our customers.”
“We’re excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments,” added Ben Castro, vice president and general manager, Large Molecule, pharma services, Thermo Fisher.
To view another recent GEN article involving exosomes, see “PlantForm, Baiya Phytopharm, and The DABOM Collaborate on the Production of Artificial Exosomes.”
The post RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.
The combination of RoosterBio’s portfolio of hMSC-based products and processes with Thermo Fisher’s advanced therapy GMP contract manufacturing capabilities is designed to offer a new solution for the development and manufacture of hMSC and exosome therapeutics, noted officials at both companies.
Complementary skills
Specifically, according to Tim Kelly, CEO of RoosterBio, biopharmaceutical companies will be able to utilize RoosterBio’s and Thermo Fisher’s complementary skills to accelerate their timelines for production of clinical trial materials. Manufacturing services provided by Thermo Fisher will include upstream expansion of hMSCs, downstream purification of MSCs and MSC-derived exosomes, and drug product manufacturing.
“Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities,” said Kelly. “Through this collaboration, we will deliver that comprehensive solution to our customers.”
“We’re excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments,” added Ben Castro, vice president and general manager, Large Molecule, pharma services, Thermo Fisher.
To view another recent GEN article involving exosomes, see “PlantForm, Baiya Phytopharm, and The DABOM Collaborate on the Production of Artificial Exosomes.”
The post RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.